We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Read MoreHide Full Article
McKesson (MCK - Free Report) reported $74.48 billion in revenue for the quarter ended June 2023, representing a year-over-year increase of 10.9%. EPS of $7.27 for the same period compares to $5.83 a year ago.
The reported revenue represents a surprise of +6.55% over the Zacks Consensus Estimate of $69.91 billion. With the consensus EPS estimate being $5.85, the EPS surprise was +24.27%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how McKesson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- U.S. Pharmaceutical: $67.16 billion versus $61.56 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +17.9% change.
Revenue- Prescription Technology Solutions: $1.24 billion versus the three-analyst average estimate of $1.16 billion. The reported number represents a year-over-year change of +16.7%.
Revenue- International: $3.47 billion compared to the $3.81 billion average estimate based on three analysts. The reported number represents a change of -47.1% year over year.
Revenue- Medical-Surgical Solutions: $2.61 billion compared to the $2.60 billion average estimate based on three analysts. The reported number represents a change of +0.7% year over year.
Adjusted Operating Profit- U.S. Pharmaceutical: $771 million compared to the $711.12 million average estimate based on two analysts.
Adjusted Operating Profit- International: $90 million versus $99.21 million estimated by two analysts on average.
Adjusted Operating Profit- Corporate: -$149 million compared to the -$151.97 million average estimate based on two analysts.
Adjusted Operating Profit- Prescription Technology Solutions: $223 million versus $180.38 million estimated by two analysts on average.
Adjusted Operating Profit- Medical-Surgical Solutions: $235 million versus the two-analyst average estimate of $226.27 million.
Shares of McKesson have returned -3.8% over the past month versus the Zacks S&P 500 composite's +3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
McKesson (MCK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
McKesson (MCK - Free Report) reported $74.48 billion in revenue for the quarter ended June 2023, representing a year-over-year increase of 10.9%. EPS of $7.27 for the same period compares to $5.83 a year ago.
The reported revenue represents a surprise of +6.55% over the Zacks Consensus Estimate of $69.91 billion. With the consensus EPS estimate being $5.85, the EPS surprise was +24.27%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how McKesson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- U.S. Pharmaceutical: $67.16 billion versus $61.56 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +17.9% change.
- Revenue- Prescription Technology Solutions: $1.24 billion versus the three-analyst average estimate of $1.16 billion. The reported number represents a year-over-year change of +16.7%.
- Revenue- International: $3.47 billion compared to the $3.81 billion average estimate based on three analysts. The reported number represents a change of -47.1% year over year.
- Revenue- Medical-Surgical Solutions: $2.61 billion compared to the $2.60 billion average estimate based on three analysts. The reported number represents a change of +0.7% year over year.
- Adjusted Operating Profit- U.S. Pharmaceutical: $771 million compared to the $711.12 million average estimate based on two analysts.
- Adjusted Operating Profit- International: $90 million versus $99.21 million estimated by two analysts on average.
- Adjusted Operating Profit- Corporate: -$149 million compared to the -$151.97 million average estimate based on two analysts.
- Adjusted Operating Profit- Prescription Technology Solutions: $223 million versus $180.38 million estimated by two analysts on average.
- Adjusted Operating Profit- Medical-Surgical Solutions: $235 million versus the two-analyst average estimate of $226.27 million.
View all Key Company Metrics for McKesson here>>>Shares of McKesson have returned -3.8% over the past month versus the Zacks S&P 500 composite's +3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.